Kate Newbold

14.4k total citations · 6 hit papers
143 papers, 9.3k citations indexed

About

Kate Newbold is a scholar working on Endocrinology, Diabetes and Metabolism, Otorhinolaryngology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Kate Newbold has authored 143 papers receiving a total of 9.3k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Endocrinology, Diabetes and Metabolism, 48 papers in Otorhinolaryngology and 32 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Kate Newbold's work include Thyroid Cancer Diagnosis and Treatment (69 papers), Head and Neck Cancer Studies (48 papers) and Advanced Radiotherapy Techniques (19 papers). Kate Newbold is often cited by papers focused on Thyroid Cancer Diagnosis and Treatment (69 papers), Head and Neck Cancer Studies (48 papers) and Advanced Radiotherapy Techniques (19 papers). Kate Newbold collaborates with scholars based in United Kingdom, United States and Italy. Kate Newbold's co-authors include Kevin J. Harrington, Christopher M. Nutting, Shreerang Bhide, Rossella Elisei, Sophie Leboulleux, Manisha H. Shah, Marcia S. Brose, Steven I. Sherman, Bruce Robinson and Martin Schlumberger and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Kate Newbold

136 papers receiving 9.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer

2015 1.4k citations Martin Schlumberger, Lori J. Wirth et al. profile →
Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial

2011 1.2k citations Christopher M. Nutting, James P. Morden et al. The Lancet Oncology profile →
Guidelines for the management of thyroid cancer

2014 899 citations Kate Newbold et al. profile →
Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2019 730 citations Kate Newbold et al. Annals of Oncology profile →
2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer

2021 374 citations Keith C. Bible, Maria E. Cabanillas et al. profile →
Thyroid cancer

2023 287 citations Kate Newbold et al. profile →

Peers

Countries citing papers authored by Kate Newbold

Since Specialization

Citations

This map shows the geographic impact of Kate Newbold's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kate Newbold with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kate Newbold more than expected).

Fields of papers citing papers by Kate Newbold

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kate Newbold. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kate Newbold. The network helps show where Kate Newbold may publish in the future.

Co-authorship network of co-authors of Kate Newbold

This figure shows the co-authorship network connecting the top 25 collaborators of Kate Newbold. A scholar is included among the top collaborators of Kate Newbold based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kate Newbold. Kate Newbold is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Targeting RET in medullary thyroid cancer 2025 ·Endocrine Related Cancer ·Kate Newbold, (unknown)	0
2	Prevalence of depressive and anxiety symptoms in patients with head and neck cancer undergoing radiotherapy: A systematic review and meta-analysis of longitudinal studies 2024 ·Radiotherapy and Oncology ·(unknown), Clàudia Aymerich, Antonio Rullan, Jon Cacicedo, (unknown), Christopher M. Nutting, Kate Newbold, Kevin J. Harrington, Ana Catalán	1
3	Genomic landscape of anaplastic thyroid cancer and implications on therapy 2023 ·Current Opinion in Endocrine and Metabolic Research ·(unknown), Kate Newbold	2
4	2212MO Major secondary outcomes in the multicentre noninferiority randomised trial IoN: Is ablative radioiodine necessary for low-risk differentiated thyroid cancer patients? 2023 ·Annals of Oncology ·Allan Hackshaw, Kate Newbold, Matthew Beasley, Kate Garcez, Jonathan Wadsley, Susan K. Johnson, Terence Stephenson, Mark N. Gaze, A. Goodman, Susan Jeffries, D. Wilkinson, Elena Atienza Macías, David A. Power, Tom Roques, (unknown), Gareth Gerrard, Sharon Forsyth, Ellen T. Chang, Kate Farnell, Ujjal K. Mallick	3
5	On-treatment immune prognostic score for patients with relapsed and/or metastatic head and neck squamous cell carcinoma treated with immunotherapy 2021 ·Journal for ImmunoTherapy of Cancer ·Pablo Nenclares, (unknown), (unknown), (unknown), (unknown), Isla Leslie, Kee H. Wong, Alan Melcher, Kate Newbold, Chris Nutting, Derfel ap Dafydd, Shreerang Bhide, Kevin J. Harrington	29
6	Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer 2021 ·Journal of Clinical Oncology ·Lori J. Wirth, Marcia S. Brose, Eric J. Sherman, Lisa Licitra, Martin Schlumberger, Steven I. Sherman, Keith C. Bible, Bruce Robinson, Patrice Rodien, Yann Godbert, Christelle de la Fouchardière, Kate Newbold, Christopher M. Nutting, Soamnauth Misir, Ran Xie, (unknown), (unknown), Maria E. Cabanillas	83
7	Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer 2020 ·Journal for ImmunoTherapy of Cancer ·(unknown), Katharina Bergerhoff, (unknown), Shane Foo, Emmanuel C. Patin, (unknown), Richard Buus, Syed Haider, Gareth Muirhead, Khin Thway, Kate Newbold, Robert S. Coffin, Richard G. Vile, Dae Joon Kim, Martin McLaughlin, Alan Melcher, Kevin J. Harrington, Malin Pedersen	24
8	Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study 2018 ·Clinical Cancer Research ·Magnus T. Dillon, Lorna Grove, Kate Newbold, Heather M. Shaw, Nicholas F. Brown, Jeanne Mendell, Shuquan Chen, Robert A. Beckman, Anne Jennings, Marivic Ricamara, Jonathan Greenberg, Martin Förster, Kevin J. Harrington	14
9	Noninvasive Imaging of Cycling Hypoxia in Head and Neck Cancer Using Intrinsic Susceptibility MRI 2017 ·Clinical Cancer Research ·Rafał Panek, Liam Welsh, (unknown), Maria A. Schmidt, Kee H. Wong, Angela M. Riddell, Dow‐Mu Koh, Alex Dunlop, Dualta Mcquaid, James A. d’Arcy, Shreerang Bhide, Kevin J. Harrington, Christopher M. Nutting, (unknown), Cheryl Richardson, Carol Box, Suzanne A. Eccles, Martin O. Leach, Simon P. Robinson, Kate Newbold	32
10	Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial 2017 ·Journal of Clinical Oncology ·Marcia S. Brose, Francis P. Worden, Kate Newbold, Matthew Guo, Arti Hurria	135
11	Incorporating spatial dose metrics in machine learning-based normal tissue complication probability (NTCP) models of severe acute dysphagia resulting from head and neck radiotherapy 2017 ·Clinical and Translational Radiation Oncology ·Jamie Dean, Kee H. Wong, Hiram A. Gay, Liam Welsh, (unknown), (unknown), Jung Hun Oh, Aditya Apte, Kate Newbold, Shreerang Bhide, Kevin J. Harrington, Joseph O. Deasy, Christopher M. Nutting, S. Gulliford	29
12	Survey on Paediatric Differentiated Thyroid Cancer Care in Europe 2017 ·Hormone Research in Paediatrics ·(unknown), Kate Newbold, Dagmar Führer, Steven G. Waguespack, Daria Handkiewicz-Junak, Thera P. Links	7
13	Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei 2016 ·Molecular Cancer Therapeutics ·Magnus T. Dillon, Holly E. Barker, Malin Pedersen, Hind Hafsi, Shreerang Bhide, Kate Newbold, Christopher M. Nutting, Martin McLaughlin, Kevin J. Harrington	82
14	A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer 2015 ·Clinical Cancer Research ·Martin Schlumberger, Barbara Jarząb, Maria E. Cabanillas, Bruce Robinson, Furio Pacini, Douglas W. Ball, Judith C. McCaffrey, Kate Newbold, Roger Allison, Renato Martins, Lisa Licitra, Manisha H. Shah, Donald Bodenner, Rossella Elisei, Lynn A. Burmeister, Yasuhiro Funahashi, Min Ren, James P. O'Brien, Steven I. Sherman	184
15	Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies 2012 ·Clinical Cancer Research ·Eleni Karapanagiotou, Victoria Roulstone, Katie Twigger, (unknown), Mary Anne Tanay, Chris Nutting, Kate Newbold, Martin Gore, James Larkin, Konstantinos N. Syrigos, Matt Coffey, Brad Thompson, K.L. Mettinger, Richard G. Vile, Hardev Pandha, Geoff Hall, Alan Melcher, John Chester, Kevin J. Harrington	151
16	Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial breakdown → 2011 ·The Lancet Oncology ·Christopher M. Nutting, James P. Morden, Kevin J. Harrington, Teresa Guerrero Urbano, Shreerang Bhide, Catharine H. Clark, Elizabeth Miles, Aisha Miah, Kate Newbold, Mary Anne Tanay, F. Adab, Sarah Jefferies, Christopher Scrase, B. Yap, Roger A’Hern, Mark Sydenham, Marie A. Emson, Emma Hall	1202
17	Phase I/II Study of Oncolytic HSVGM-CSF in Combination with Radiotherapy and Cisplatin in Untreated Stage III/IV Squamous Cell Cancer of the Head and Neck 2010 ·Clinical Cancer Research ·Kevin J. Harrington, Mohan Hingorani, Mary Anne Tanay, Jennifer Hickey, Shreerang Bhide, Peter Clarke, (unknown), Khin Thway, Amen Sibtain, Iain A. McNeish, Kate Newbold, Howard Goldsweig, Robert S. Coffin, Christopher M. Nutting	216
18	Two-Stage Phase I Dose-Escalation Study of Intratumoral Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers 2010 ·Clinical Cancer Research ·Kevin J. Harrington, Eleni Karapanagiotou, Victoria Roulstone, Katie Twigger, Christine L. White, Laura Vidal, (unknown), Robin Prestwich, Kate Newbold, Merina Ahmed, Khin Thway, Christopher M. Nutting, Matt Coffey, Dean Harris, Richard G. Vile, Hardev Pandha, Johann S. de Bono, Alan Melcher	94
19	External Beam Radiotherapy for Differentiated Thyroid Cancer 2010 ·Clinical Oncology ·Ceri Powell, Kate Newbold, Kevin J. Harrington, Shreerang Bhide, Christopher M. Nutting	10
20	A Phase I study to evaluate the feasibility, safety and biological effects of intratumoural administration of wild-type Reovirus (REOLYSIN (R)) in combination with radiation in patients with advanced malignancies. 2007 ·Molecular Cancer Therapeutics ·(unknown), Laura Vidal, Alan Melcher, Kate Newbold, (unknown), (unknown), Rajiv Agarwal, Christine White, Katie Twigger, Matt Coffey, K.L. Mettinger, Bruce Thompson, H. Pandha, Johann S. de Bono, Kevin J. Harrington	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact